Why the study?
Is sequential administration of ombrabulin and docetaxel feasible in patients with advanced solid tumours?
Is sequential administration of ombrabulin and docetaxel feasible in patients with advanced solid tumours?
A phase I study demonstrates that sequential administration of ombrabulin and docetaxel is feasible for advanced solid tumors.
Supports phase II evaluation in advanced solid tumors; leaves open efficacy and survival impact.
Sequential administration of ombrabulin with 75 or 100 mg m(-2) docetaxel every 3 weeks is feasible.
No takes yet. Share an insight, caveat, or question.
Eskens et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: